Mrs Linda Faye Munderloh, LPN | |
708 Main St, Bancroft, NE 68004-3014 | |
(402) 648-3336 | |
(402) 648-3338 |
Full Name | Mrs Linda Faye Munderloh |
---|---|
Gender | Female |
Speciality | Licensed Practical Nurse |
Location | 708 Main St, Bancroft, Nebraska |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1639652845 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
164W00000X | Licensed Practical Nurse | 10653 (Nebraska) | Primary |
Mailing Address | Practice Location Address |
---|---|
Mrs Linda Faye Munderloh, LPN Po Box 129, Bancroft, NE 68004-0129 Ph: (402) 648-3336 | Mrs Linda Faye Munderloh, LPN 708 Main St, Bancroft, NE 68004-3014 Ph: (402) 648-3336 |
News Archive
A new study uncovers which cell types can be infected by SARS-CoV-2 due to their viral entry factors. The study also suggests that increased gene expression of these viral entry factors in some individuals partially explains the differences of COVID-19 severity reported in relation to age, gender and smoking status.
"Being tired can be as bad as being drunk, in terms of its effect upon performance," says safety expert, Dr Ann Williamson, who led the study by the University of NSW Injury Risk Management Research Centre.
Shengtai Pharmaceutical, Inc. announced on August 6, 2010 that Weifang Shengtai Pharmaceutical Co., Ltd ("Weifang Shengtai"), its operating subsidiary in China, entered into an agreement with Kelun Pharmaceutical ("Kelun") to supply Kelun with 10 thousand tons of dextrose monohydrate injection grade: Kelun Guizhou will be supplied with 7 hundred tons and Kelun Sichuan with 9.3 thousand tons. The agreement is entered into at reasonable prices and will be carried out by prepayments.
The herbal extract of a yellow-flowered mountain plant indigenous to the Arctic regions of Europe and Asia increased the lifespan of fruit fly populations, according to a University of California, Irvine study.
Turnstone Biologics today announced it has received U.S. Food and Drug Administration clearance of its Investigational New Drug Application for MG1-HPV for the treatment of patients with human papillomavirus positive solid tumors.
› Verified 9 days ago